Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Dec 8;22(1):507.
doi: 10.1186/s12876-022-02604-3.

Effect of Helicobacter pylori eradication on metabolic profile: an international, multicenter, case-control study

Pezhman Alavinejad  1 , Eskandar Hajiani  2 , Abazar Parsi  2 , Azam Satari  2 , Mohammad Javad Rezaei  2 , Morteza Nayebi  3 , Ahmad Hormati  4 , Omid Eslami  5 , Mohammed Hussien Ahmed  6 , Quang Trung Tran  7 , Masoud Arshadzadeh  8 , Siamak Baghaei  2 , Samira Mohammadi  2 , Seyed Jalal Hashemi  2 , Alireza Sedaghat  2
Affiliations
Multicenter Study

Effect of Helicobacter pylori eradication on metabolic profile: an international, multicenter, case-control study

Pezhman Alavinejad et al. BMC Gastroenterol. .

Abstract

Background: As a gram-negative and microaerophilic bacterium, Helicobacter pylori (HP) is the main cause of chronic gastritis. Therefore, considering the high prevalence of HP infection worldwide, as well as the increasing prevalence of metabolic disorders, the present study aimed to investigate the relationship between HP infection eradication and metabolic profile.

Methods: This prospective case-control study was performed on patients with HP infection whom referred to 7 medical centers in 3 countries (Iran, Egypt, and Vietnam) in 2020-2021. The metabolic profile of all of the participants evaluated before starting of treatment for HP eradication and 3 months after the treatment. Then changes of metabolic profile compared between those with successful HP eradication (group A) and subjects who failed to eradicate (group B).

Results: Overall, 199 patients, including 93 male (46.7%) with the mean age of 44.5 years (18-93 years) included. Based on response to treatment, the participants allocate into group A (those who respond to HP eradication): 164 cases (82.42%); or group B as those who failed to achieve eradication (35 cases, 17.58%). Racially 86.9% of participants were Caucasian and 89% diagnosed as non-ulcer dyspepsia (NUD). The most prevalent comorbidity include hypertension (11.5%) and hyperlipidemia (10%) which were more prevalent in group B (P = 0.002). Three months after therapy, average weight of participants among those who achieved eradication (group A) decreased from 73.1 to 71.4 kg (P = 0.01), but in comparison with group B, was non-significant (P = 0.171). The BMI of patients before and after treatment did not show any significant differences. The biochemical parameters of patients before and after treatment were not significantly different regardless of treatment success (P > 0.05). The levels of total cholesterol and VLDL cholesterol after treatment were not significantly different from baseline values in two groups. HDL and LDL cholesterol levels before and after treatment in the resistant group were significantly higher than the responding group. Average serum TG level decreased significantly after treatment in the group A (P < 0.0001), in contrast to the resistant group (P = 0.356). The liver transaminases (AST and ALT) before and after treatment were not significantly different between the two groups (P > 0.05). The results of logistic regression showed that the eradication of infection has no significant affect any of the metabolic profile parameters.

Conclusion: HP infection treatment in individuals without significant metabolic disorders does not affect metabolic parameters up to 3 months after eradication. HP eradication among subjects with several comorbidities mandates eradication protocol intensification to avoid treatment failure.

Keywords: Eradication; Helicobacter pylori; Metabolic profile.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Clinical diagnosis of participants (PUD Peptic ulcer disease; DU Duodenal ulcer; GU Gastric ulcer; IM Intestinal metaplasia; NUD Non-ulcer dyspepsia)
See this image and copyright information in PMC

References

    1. Diaconu S, Predescu A, Moldoveanu A, Pop CS, Fierbințeanu-Braticevici C. Helicobacter pylori infection: old and new. J Med Life. 2017;10(2):112–7. - PMC - PubMed
    1. Cho J, Prashar A, Jones NL, Moss SF. Helicobacter pylori infection. Gastroenterol Clin North Am. 2021;50(2):261–82. doi: 10.1016/j.gtc.2021.02.001. - DOI - PubMed
    1. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM. Management of Helicobacter pylori infection—the maastricht IV/florence consensus report. Gut. 2012;61(5):646–64. doi: 10.1136/gutjnl-2012-302084. - DOI - PubMed
    1. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–9. doi: 10.1053/j.gastro.2017.04.022. - DOI - PubMed
    1. Crowe SE. Helicobacter pylori infection. New Engl J Med. 2019;380(12):1158–1165. doi: 10.1056/NEJMcp1710945. - DOI - PubMed

Publication types